Mar 2022 $8 M No. 7 $2 to $10 million 1
High Throughput Genomics Inc.: Raise no. 7, Mar 2022 × Investors in this round 1 investor had bought by the notice of Mar 25, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $21 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $292,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Lubniewski · Executive Officer, Director Shaun McMeans · Executive Officer Ann F. Hanham · Director Christopher R. Kiritsy · Director Don M. Hardison · Director Harry A. George · Director James T. LaFrance · Director Lee R. McCracken · Director Michelle R. Griffin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Cantor Fitzgerald & Co. (CRD 134) · New York, New York Sold in NY Remarks in the notice On the amounts: “Includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase common stock (assuming no cashless exercise).”Signed by Shaun D. McMeans, SVP and CFO. Source: SEC Form D, newest notice filed Mar 25, 2022. Read the notice at the SEC .
equity, options SEC Sep 2019 $3 M No. 6 $2 to $10 million 2
High Throughput Genomics Inc.: Raise no. 6, Sep 2019 × Investors in this round 2 investors had bought by the notice of Oct 1, 2019: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $4 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $207,809
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Lubniewski · Executive Officer, Director Shaun B. McMeans · Executive Officer Ann F. Hanham · Director Don M. Hardison · Director Harry A. George · Director James T. LaFrance · Director Lee R. McCracken · Director Michelle R. Griffin · Director Timothy B. Johnson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Cantor Fitzgerald & Co. (CRD 134) · New York, New York Sold in CA, OR Remarks in the notice On the amounts: “Total Amount Sold represents the amount received by the Issuer from the sale of pre-funded warrants to purchase common stock. Total Remaining to be Sold represents amount receivable by the Issuer upon cash exercise of such pre-funded warrants.”Signed by Shaun D. McMeans, SVP Fin & Admin and CFO. Source: SEC Form D, newest notice filed Oct 1, 2019. Read the notice at the SEC .
options SEC Feb 2014 $7 M No. 5 $2 to $10 million 15
High Throughput Genomics Inc.: Raise no. 5, Feb 2014 × Investors in this round 15 investors had bought by the notice of Feb 13, 2014: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $22 M offered; $14 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Shaun McMeans · Executive Officer Timothy Johnson · Executive Officer, Director Harry George · Director Jim Weersing · Director Larry Senour · Director Molly Hoult · Director Peter Bisgaard · Director Simeon George · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total Offering Amount includes amounts receivable by the Issuer upon the exercise of warrants to purchase the Issuer's Series E Preferred Stock.”Signed by Shaun McMeans, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 13, 2014. Read the notice at the SEC .
equity, options SEC Nov 2012 $8 M No. 4 $2 to $10 million 9
High Throughput Genomics Inc.: Raise no. 4, Nov 2012 × Investors in this round 9 investors had bought by the notice of Nov 14, 2012: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $27 M offered; $19 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Shaun W. McMeans · Executive Officer Timothy Johnson · Executive Officer, Director Donald W. Grimm · Director Harry George · Director Jim Weersing · Director Larry Senour · Director Molly W. Hoult · Director Peter W. Bisgaard · Director Simeon W. George · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Shaun McMeans, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 14, 2012. Read the notice at the SEC .
equity SEC Feb 2011 $14 M No. 3 $10 to $50 million 30
High Throughput Genomics Inc.: Raise no. 3, Feb 2011 × Investors in this round 30 investors had bought by the notice of Jun 17, 2011: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $14 M of $14 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kirk A. Collamer · Executive Officer Timothy Johnson · Executive Officer, Director Donald W. Grimm · Director Harry A. George · Director Jim A. Weersing · Director Larry A. Senour · Director Molly W. Hoult · Director Peter W. Bisgaard · Director Simeon W. George · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kirk A. Collamer, VP and Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 17, 2011. Read the notice at the SEC .
equity SEC Jul 2010 $2 M No. 2 Under $2 million 22
High Throughput Genomics Inc.: Raise no. 2, Jul 2010 × Investors in this round 22 investors had bought by the notice of Aug 6, 2010: 22 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kirk A. Collamer · Executive Officer Timothy Johnson · Executive Officer, Director Bruce E. Seligmann · Director Donald W. Grimm · Director Harry M. George · Director Jim A. Weersing · Director John M. Holliman · Director Larry E. Senour · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kirk A. Collamer, VP and Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 6, 2010. Read the notice at the SEC .
debt, options SEC Nov 2008 $4 M No. 1 $2 to $10 million 7
High Throughput Genomics Inc.: Raise no. 1, Nov 2008 × Investors in this round 7 investors had bought by the notice of Jul 23, 2009: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for High Throughput Genomics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Series C-2 Convertible Preferred Stock
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kirk A. Collamer · Executive Officer Timothy Johnson · Executive Officer, Director Bruce E. Seligmann · Director Donald W. Grimm · Director Harry George · Director Jim Weersing · Director John M. Holliman · Director Larry Senour · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kirk A. Collamer, VP and Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 23, 2009. Read the notice at the SEC .
equity SEC